, Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.20, issue.15, pp.3262-3269, 2002.
DOI : 10.1200/JCO.2002.11.017
, Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008.
DOI : 10.1200/JCO.2008.17.2015
, Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients, Clinical Cancer Research, vol.16, issue.15, pp.3998-4004, 2010.
DOI : 10.1158/1078-0432.CCR-10-0162
URL : http://clincancerres.aacrjournals.org/content/clincanres/16/15/3998.full.pdf
, Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90???Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499, Journal of Clinical Oncology, vol.30, issue.25, pp.3119-3126, 2012.
DOI : 10.1200/JCO.2012.42.2444
URL : http://europepmc.org/articles/pmc3732008?pdf=render
, High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.28, issue.23, pp.3709-3716, 2010.
DOI : 10.1200/JCO.2009.27.7863
, Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, Journal of Clinical Oncology, vol.28, issue.18, pp.2944-2946, 2010.
DOI : 10.1200/JCO.2009.26.8748
, Radioimmunotherapy of human tumours, Nature Reviews Cancer, vol.9, issue.6, pp.347-360, 2015.
DOI : 10.4161/cbt.6.6.4089
URL : http://europepmc.org/articles/pmc4798425?pdf=render
, I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results, Journal of Clinical Oncology, vol.23, issue.27, pp.6763-6770, 2005.
DOI : 10.1200/JCO.2005.18.622
, Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.41, issue.S4, pp.1332-1348, 2002.
DOI : 10.4049/jimmunol.164.3.1432
, Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.308-313, 2012.
DOI : 10.1200/JCO.2011.41.1553
, Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria, Journal of Clinical Oncology, vol.32, issue.3, pp.212-218, 2013.
DOI : 10.1200/JCO.2013.50.3110
, Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer, Clinical Cancer Research, vol.19, issue.18, pp.5182-5191, 2013.
DOI : 10.1158/1078-0432.CCR-13-0231
URL : http://clincancerres.aacrjournals.org/content/clincanres/19/18/5182.full.pdf
, Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC)., Journal of Clinical Oncology, vol.33, issue.7_suppl, p.194, 2015.
DOI : 10.1200/jco.2015.33.7_suppl.194
, Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006.
DOI : 10.1200/JCO.2005.03.8471
, Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti???Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group, Journal of Clinical Oncology, vol.24, issue.11, pp.1705-1711, 2006.
DOI : 10.1200/JCO.2005.04.4917
, Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012.
DOI : 10.2967/jnumed.111.101865
URL : https://hal.archives-ouvertes.fr/hal-00932253
, Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy, Seminars in Nuclear Medicine, vol.40, issue.3, pp.190-203, 2010.
DOI : 10.1053/j.semnuclmed.2009.12.002
URL : http://europepmc.org/articles/pmc2855818?pdf=render
, Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails, J Immunol, vol.146, pp.169-175, 1991.
, Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens, Bioconjugate Chemistry, vol.11, issue.4, pp.452-460, 2000.
DOI : 10.1021/bc9901090
, Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates, Journal of Nuclear Medicine, vol.57, issue.3, pp.444-452, 2016.
DOI : 10.2967/jnumed.115.162339
URL : http://jnm.snmjournals.org/content/57/3/444.full.pdf
, Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer, Cancer, vol.6, issue.suppl, pp.5497-5506, 2012.
DOI : 10.1016/S1040-8428(00)00136-0
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.27592/pdf
, Immune Checkpoint Blockade in Cancer Therapy, Journal of Clinical Oncology, vol.33, issue.17, pp.1974-1982, 2015.
DOI : 10.1200/JCO.2014.59.4358
, Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges, Cancer Letters, vol.365, issue.1, pp.23-29, 2015.
DOI : 10.1016/j.canlet.2015.05.012
, Theragnostic Imaging Using Radiolabeled Antibodies and Tyrosine Kinase Inhibitors, The Scientific World Journal, vol.22, issue.16, p.842101, 2015.
DOI : 10.1016/j.nucmedbio.2013.02.002
URL : http://downloads.hindawi.com/journals/tswj/2015/842101.pdf